Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome

Anat Galor, Timothy O'Brien

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

Original languageEnglish (US)
Pages (from-to)335-336
Number of pages2
JournalInternational journal of hematology
Issue number4
StatePublished - Nov 2003
Externally publishedYes


  • Immune hemolytic anemia
  • Rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome'. Together they form a unique fingerprint.

Cite this